Effect of Fluosol-DA on the blood coagulation/fibrinolytic system and the renin-angiotensin system in man.
Either F-DA, Ringer's lactate or HES was given to three groups of six patients each who were undergoing elective gynecologic surgery, and their effects on the blood coagulation/fibrinolytic systems, and the renin-angiotensin systems were evaluated. Platelet counts were found to increase markedly using the Coulter Counter method, but no change was observed when the Rees-Ecker method was used. Platelet aggregation was inhibited and AT-III concentrations were decreased by administration of F-DA. There were no significant changes in PT or a-PTT as a result of F-DA administration. Similarly, there were no significant changes in the concentrations of fbg, FDP, a2-PI, P-FN and renin, angiotensin I, II and angiotensin converting enzyme following F-DA administration. Based upon these findings, it is suggested that a clinical dosage of 20 to 30 ml/kg of F-DA can be safely administered to patients with normal platelet and RES function.
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D001802:Blood Substitutes / Q000494:pharmacology*; D004338:Drug Combinations / Q000494:pharmacology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects*; D005353:Fibronectins / Q000097:blood; D005466:Fluorocarbons / Q000494:pharmacology*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D012084:Renin-Angiotensin System / Q000187:drug effects*
D001802:Blood Substitutes; D004338:Drug Combinations; D005338:Fibrin Fibrinogen Degradation Products; D005353:Fibronectins; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination